USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: TSRL, INC.
City: ANN ARBOR
State: MI
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $5,476,185.00 24
SBIR Phase II $8,600,232.00 7

Award List:

TECHNOLOGY FOR ORAL DELIVERY OF FIRST-PASS DRUGS

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Glen d leesman
Award Amount: $47,000.00
Abstract:
Strategies for reducing the dosing interval of orally absorbed drugs rely on changing the release pattern of the drug from the delivery system so that the blood level profile of the drug falls within the therapeutic window overthe time of the dosing interval. however, for drugs that exhibit… More

POSITION-SENSITIVE SCINTILLATION FLOW COUNTER

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ralph s conti phd
Award Amount: $50,000.00

TOPICAL DELIVERY OF LIPOSOMALLY ENCAPSULATED INTERFERON

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chandrasekharan, Ramachan , Principal Investigator
Award Amount: $50,000.00

POSITION-SENSITIVE SCINTILLATION FLOW COUNTER

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ralph s conti phd
Award Amount: $456,131.00
Abstract:
A novel principle for simultaneous scintillation counting of multiple radioactive samples is proposed. the immediate goal of this proposal is to construct and test a six-sample prototype device to prove the practical applicability of the principle involved. the long-term goal is to develop a device… More

TECHNOLOGY FOR IMPROVED ORAL DELIVERY OF ANTI-HIV DRUGS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Glen D Leesman
Award Amount: $50,000.00
Abstract:
The long-term objective is to develop an oral drug delivery strategy and technology base to increase the extent of absorption and decrease the variability of the absorption of nucleotide antiviral drug analogs in humans. 2', 3'-dideoxyinosine (videx tm, ddi) is a purine nucleosidedrug analog that is… More

TOPICAL DELIVERY OF LIPOSOMALLY ENCAPSULATED INTERFERON

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Chandrasekharan, Ramachan , Principal Investigator
Award Amount: $484,173.00
Abstract:
About five million americans suffer from genital herpes, with an estimated one-half million individuals having become infected in 1981 alone. although many forms of therapy have been tested, none has proven profoundly beneficial in decreasing the severity and frequency of the clinical… More

Targeted Delivery of Recombinant Adenovirus to Gut

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Hilfinger
Award Amount: $81,000.00
Abstract:
Inflammatory bowel disease (IBD) is a collective term that includes Crohn's disease andulcerative colitis. Although both disorders have a distinct clinical course with characteristicpathophysiology, the destructive and progressive course of IBD probably is due to persistent elevatedexpression of… More

"Protected" Nanoparticles for an Oral Single-Dose Staphylocaccal Enterotoxin B Vaccine

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Vinod Labhasetwar
Award Amount: $69,902.00
Abstract:
Conventional methods of immunization in general require multiple injections at certain intervals to achieve the required protective immune response. However, this immunization protocol may not always be practical, especially for Army personnel in the field or in remote areas where access to the… More

Adenoviral Mediated Gene Therapy for Experimental Glioma

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Hilfinger
Award Amount: $100,000.00

DIPEPTIDE TRANSPORTER EXPRESSION IN VITRO

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

PRODRUGS OF BISPHOSPHONATE FOR CALCIUM RELATED DISORDERS

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

Adenoviral Mediated Gene Therapy for Experimental Glioma

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator: John Hilfinger
Award Amount: $632,576.00
Abstract:
Gliomas are the most common primary intracranial brain tumors and are thought to arise as a neoplastransformation of glial cells in the central nervous system. The prognosis for the disease is poor.surgical resection of the tumor followed by radiation or chemotherapy. This application describes… More

N/A

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $749,970.00

DIPEPTIDE TRANSPORTER EXPRESSION IN VITRO

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $692,136.00

ORAL DELIVERY OF ENCAPSULATED MULTIMERIC AIDS VACCINES

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Hilfinger
Award Amount: $155,244.00
Abstract:
Not Available This Phase I SBIR proposal is aimed at developing a design capability and comprehensive set of simulation tools for exploring the feasibility and making a realistic assessment of the potential for advanced rocket propulsion based on the Pulsed Detonation Engine (PDE) cycle. The PDE is… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $180,297.00

MODELS FOR SCREENING INTESTINAL TRANSPORTER PRODRUGS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phillip E. Kish
Award Amount: $188,924.00
Abstract:
DESCRIPTION (provided by applicant): Recently, it has been shown that a variety of drugs require carrier-mediated transport (e.g., the human dipeptide transporter or hpepT1) in order to cross the cell membrane and be absorbed into the body. Although the use of membrane transporters to enhance drug… More

DEVELOPMENT OF AN ORAL ANTHRAX VACCINE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $203,609.00
Abstract:
DESCRIPTION (provided by applicant): Of the numerous biological agents that may be used as weapons, the Working Group on Civilian Biodefense has identified Bacillus anthracis as one of the most serious agents. The most effective defense against this agent on a broad scale is through an aggressive… More

Improving Absorption and Targeting of Antiviral Drugs

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $926,954.00
Abstract:
DESCRIPTION (provided by investigator): With recent unsettling events foreshadowing an increased sense of urgency, NIAID has targeted research and development of therapeutics, vaccines, adjuvants/immunostimulants, and diagnostics for small pox and other viral diseases. At TSRL, Inc., we have been… More

Oral Delivery of Thrombostatin

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $205,333.00
Abstract:
DESCRIPTION (provided by applicant): The hypothesis of this proposal is that the di- or tri-peptide transporter in the gastrointestinal tract can be used as a means to absorb orally delivered peptides as therapeutics in vivo. Recent information indicates that the bradykinin breakdown product of… More

Enhancing Thrombostatin's Oral Delivery

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $274,452.00
Abstract:
DESCRIPTION (provided by applicant): The long term objective of the project is to develop an orally bioavailable drug for treatment of individuals with acute coronary syndromes (ACS) and also individuals whose cancer is influenced by the mitogenic effects of thrombin. Current therapy for the acute… More

Bile acid conjugates to improve the oral bioavailability of anti-influenza drugs

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Phillip Kish
Award Amount: $299,314.00
Abstract:
DESCRIPTION (provided by applicant): With the concern for an avian influenza pandemic increasing, there is a need to develop antiviral therapies with improved bioavailability. We are developing an enhanced oral delivery platform for anionic small molecule antiviral drugs using zanamivir as our… More

Improving Absorption and Targeting of Antiviral Drugs

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): With recent unsettling events foreshadowing an increased sense of urgency, NIAID has targeted research and development of therapeutics, vaccines, adjuvants/immunostimulants, and diagnostics for smallpox (variola). TSRL was granted a Phase I SBIR to explore… More

Vidarabine Prodrugs as Anti-Pox Virus Agents

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $297,813.00
Abstract:
DESCRIPTION (provided by applicant): The Working Group for Civilian Biodefense has identified smallpox as one of the most serious biological agents that could cause disease and deaths in sufficient numbers to cripple a city or region. The National Institut e of Allergy and Infectious Disease has… More

Bile acid conjugates for improving the oral bioavailability of bisphosphonates

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $255,852.00
Abstract:
DESCRIPTION (provided by applicant): Bisphosphonates are chemically and enzymatically stable analogues of inorganic pyrophosphate that interfere with specific biochemical and enzymatic pathways of the bone-resorbing osteoclasts. The development of the bisp hosphonates has yielded effective… More

Development of orally delivered, non-absorbable AT1 receptor antagonists for infl

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $268,620.00
Abstract:
DESCRIPTION (provided by applicant): A major limitation with most current medical therapies for inflammatory bowel disease (IBD) is the indiscriminant immunosuppressive effect of these drugs. We have recently demonstrated the ability to palliate the progre ssion of colitis in a mouse dextran sodium… More

Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $185,621.00
Abstract:
DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase has garnered increasing interest in the pharmaceutical i ndustry due to their selectivity and… More

Novel prodrugs for treatment of human CMV infection

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger
Award Amount: $591,457.00
Abstract:
DESCRIPTION (provided by applicant): As a result of the widespread use of antiviral prophylaxis and pre-emptive therapy, the incidence and severity of human cytomegalovirus (HCMV) disease and its indirect effects have been significantly reduced. However, t here is an increasing recognition of… More

Development of the orally delivered, non-absorbable ACE inhibitor enalaprilat for

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elke Lipka
Award Amount: $197,747.00
Abstract:
DESCRIPTION (provided by applicant): A major limitation with most current medical therapies for inflammatory bowel disease (IBD) is the indiscriminant immunosuppressive effect of these drugs. We have recently demonstrated the ability to palliate the progre ssion of colitis in a mouse dextran sodium… More

Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: John M. Hilfinger – 734-663-4233
Award Amount: $2,585,246.00
Abstract:
DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase has garnered increasing interest in the pharmaceutical industry due to their selectivity and… More

Broad Spectrum Antiviral Nucleoside Phosphonate Analogs

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: John M. Hilfinger – 734-663-4233
Award Amount: $597,046.00
Abstract:
DESCRIPTION: The Working Group for Civilian Biodefense has identified orthopox DNA viruses such as variola as a potential bioterrorism threat, and numerous other DNA viruses, including herpes, adeno, pox, polyoma and papilloma viruses, are of general concern in a public health context, as are the… More